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Summary Twenty patients with progressive metastatic solid tumours were entered into a study to evaluate
the biological effects and toxicity of recombinant human granulocyte-macrophage colony-stimulating factor
(GM-CSF). GM-CSF was given as half-hour intravenous infusions during two 10-day phases of daily
treatments (separated by 10 days without GM-CSF) and over a final phase of 20 days of alternate day
infusions. Doses were escalated in steps from 0.3 to 60pgkg-' day-' between successive patient groups.
Significant increases (P<0.005) of total leucocyte, neutrophil and eosinophil polymorph counts were seen
over the periods of daily infusions (up to four-fold rises of total white count) at dose levels of 10pgkg-1 and
above. Counts produced at 30pgkg-' were significantly higher than at 10pgkg-' (P<0.025). Toxic side
effects of GM-CSF included mild transient pyrexias, bone pain and pruritus. The maximum tolerated dose
was 60pgkg-1, which produced severe toxicity in 80% of patients. The toxicity at this dose included
pericarditis and dyspnoea ascribed to a 'capillary-leak' syndrome. One patient receiving 60pgkg-' died as a
result of a pulmonary embolus. Seven patients with previously rapidly progressive metastatic tumours
experienced stabilisation of disease while receiving GM-CSF and one patient with a previously heavily
pretreated metastatic soft tissue sarcoma underwent a greater than 50% reduction of tumour volume. Patients
undergoing chemotherapy may benefit both from a reduction of the myelosuppressive effects of cytotoxic
agents and from an antitumour effect if GM-CSF is incorporated into future regimens.
Granulocyte macrophage colony stimulating factor (GM-
CSF) is one of a class of specific haemopoietic growth
factors first described over 20 years ago (Bradley & Metcalf,
1966). GM-CSF stimulates granulocyte and macrophage
progenitor cells to form mature colonies of granulocytes
and/or macrophages (Metcalf & Burgess, 1982), high
concentrations preferentially favouring the development of
granulocytes, and low concentrations the development of
macrophages (Metcalf, 1984).
In addition to its proliferative and differentiating activities,
GM-CSF also stimulates various functional activities of
mature granulocytes and macrophages. Granulocytes
stimulated in vitro by GM-CSF exhibit increased RNA and
protein synthesis (Stanley & Burgess, 1983), antibody-
dependent cytotoxic killing of tumour cells (Lopez et al.,
1983) and are primed to enhance oxidative metabolism in
response to certain bacterial chemo-attractants (Weisbart et
al., 1987). The migration of human peripheral neutrophils
has, however, been reported to be impaired by GM-CSF
(Gasson et al., 1986).
Administration of GM-CSF to non-human primates
results in the rapid onset of a leucocytosis, a similar response
being obtained in a pancytopaenic, immunodeficient
macaque (Donahue et al., 1986). Infusion of GM-CSF to
primates undergoing total-body irradiation and infusion of
autologous bone marrow accelerates haemopoietic recovery
(Nienhuis et al., 1987). The potential clinical value of human
haemopoietic colony stimulating factors includes their use in
reducing the degree of neutropaenia associated with marrow
aplasia - either iatrogenic (e.g. chemotherapy induced) or
idiopathic, in treating patients with deficiencies of neutrophil
function following severe trauma (e.g. after burns) and in
patients suffering from the acquired immunodeficiency
syndrome (AIDS).
The cloning of the gene for human GM-CSF was achieved
in 1985 (Cantrell et al., 1985) and recombinant DNA
technology has provided sufficient quantities of rhGM-CSF
for use in preclinical testing (Burgess et al., 1987). Rises in
peripheral neutrophil and monocyte counts have been
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observed without serious toxicity (at doses of GM-CSF up
to 300pgkg-1). We have, therefore, undertaken a phase I
study in humans to evaluate the -biological effects and
monitor the toxicity of rhGM-CSF given at increasing
dosage by 30-minute intravenous infusions.
Materials and methods
Study design
GM-CSF was administered as intravenous infusions over 30
minutes. The planned schedule was for each patient to
receive 30 infusions over 50 days with daily administration
on days 1-10 and 21-30. No GM-CSF was given between
days 11 and 20. A final phase of alternate day infusions was
given on days 31-50. The study design was for three patients
to be entered at each of the following dose levels: 0.3, 1.0,
3.0, 10, 30 and 60pgkg-1 day-1. There was no dose
escalation within the same patient. The study endpoint was a
maximum tolerated dose (MTD) resulting in a total white
cell count of 50 x 109 1-I and/or a platelet count
>600 x 109 1-1, or a severe or life-threatening toxicity in any
system (WHO grade 3/4) in 66% of patients. Six patients
were to be entered at the MTD. Comparisons of values of
different haematological parameters at specific time points in
the study for each dose level were made using a paired
Student's t test.
Patients
Twenty patients were entered into this study. All had
advanced solid tumours for which conventional therapy had
failed. Inclusion criteria were a WHO performance status of
0, 1 or 2, age greater than 18 years and a minimum period
of four weeks beyond toxicity induced by any prior cytotoxic
chemotherapy or radiation therapy (neutrophil count
> 1.5 x 109 -I and platelets > 100 x 109 -1). The patients
had normal renal function (serum creatinine
<0.12mmol -1) and serum liver enzymes elevated no more
than 1.5 times greater than the upper limit of normal. All
provided signed informed consent. Exclusion criteria
included prior radiotherapy involving more than 30% of the
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marrow volume, ongoing infections, major surgery within 14
days of study entry and women of childbearing potential.
Clinical and laboratory monitoring
Regular haematological and biochemical investigations were
performed before and during treatment with GM-CSF.
These included full blood counts (with differential and
reticulocyte count), measurement of prothrombin and partial
thromboplastin times, full biochemistry screen (including
glucose and uric acid) serum cholesterol, triglycerides, iron,
B12 and folate, creatinine clearance and urinalysis. Serum
was also regularly assayed for neutralising factors. The
clinical state of the patients was monitored by physical
examinations, recording of weight, blood pressure, radial
pulse, oral temperature and electrocardiography. In addition,
bone marrow aspirates and trephines were taken for
microscopic assessment and in vitro clonogenic assays of
haemopoietic progenitor cells before treatment and at days
10, 15 and 50. Tests for mobility and bactericidal activity of
granulocytes from peripheral blood were performed (to be
reported separately).
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Figure 1 Mean white cell count for three patients receiving
GM-CSF at dose of 30pgkg- . The change of total leucocyte
count ( ), neutrophils (*) and eosinophils (El) with time is
shown and demonstrates the triphasic rise of the count during
the first and second periods of daily infusions.
Recombinant human GM-CSF
Recombinant human GM-CSF was supplied by Schering
Corporation (New Jersey) and was produced as a non-
glycosylated protein of molecular weight 14.4 kD. It was
supplied in vials as sterile lyophilised powder and each was
reconstituted with 1 ml water. The total dose was added to
150 ml normal saline and administered over 30 minutes via a
central venous line.
Results
Twenty patients were entered into this study, three at each
dose level to 30pgkg-1 and five at 60pgkg-1. The majority
(16) had primary neoplasms arising in the gastrointestinal
tract and five patients had received prior chemotherapy.
Effects of GM-CSF on blood count
There was no significant change in any of the haematological
parameters during the administration of GM-CSF at doses
of 0.3, 1.0 or 3.0 pgkg-1 day-'. At doses of 10pgkg-1
day-1 and above, the daily total leucocyte count rose in a
triphasic fashion with an early increase over the first 48
hours, subsequent plateau phase and final further rise during
days 8-10 and 28-30 of the daily treatments to reach levels
which were 250-400% above the starting values (Figure 1).
The count fell to pretreatment levels within 72 hours of
discontinuing therapy. There was only a small increment of
the leucocyte count with alternate day dosing (at 30 and
60pugkg-1). Changes of the white cell count over 24 hours
immediately following the first infusion of GM-CSF were
examined in two patients (receiving 30 and 60pgkg-1
day-1). There was a rapid fall of the peripheral leucocyte
count so that within 5 minutes of commencing the infusion
there was a marked leucopaenia (Figure 2). The count
gradually increased and reached baseline values 4 hours
later.
The mean absolute white cell counts at different stages of
the study at each dose level are shown in Figure 3. Only one
patient was able to complete the planned 30 infusions of
GM-CSF at 60 pgkg-' because of toxicity (see below)
making full statistical analysis for this dose impossible.
Comparison of the counts produced by the first and second
10-day periods of daily infusions revealed no significant
differences between the two sets of values for the same dose
levels. Total leucocyte, neutrophil and eosinophil counts
produced by daily infusions at 10 and 30pgkg-1 were
significantly higher (P < 0.005 for each parameter) than
those produced by lower doses. The total leucocyte
(P < 0.005) and neutrophil (P < 0.025) counts produced by
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Figure 2 Profile of change in total white cell count (-) and
neutrophils (*) over 17 hours after commencement of infusion of
GM-CSF in a patient receiving a dose of 60 pgkg-'. There was
a rapid early fall of the count within 5 minutes and a return to
pretreatment levels by 4 hours later.
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Figure 3 Bar chart to demonstrate the change in mean total
white cell count for patients receiving different doses of GM-CSF.
The counts at day 0 (pretreatment), day 10 (following the first
phase of daily infusions), day 20 (after 10 days without GM-
CSF), day 30 (following the second phase of daily infusions) and
day 50 (at the end of alternate day treatment) are shown. Only
one patient completed the full 50 days on study at a dose level of
60 pgkg- .
daily administration of GM-CSF at 30pgkg- were
significantly higher than at 10pgkg-1. The dose-response
relationship of the total white count to GM-CSF is shown in
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Figure 4 Graph to demonstrate the maximum change in median
total white cell count at different dose levels of GM-CSF. Values
for percentage changes in count are plotted for the three phases
of treatment and indicate the dose-response relationship up to
30 pgkg- Cycle 1 (E) represents the first and cycle 2 (*) the
second phase of daily infusions. Cycle 3 (a) relates to the
alternate day dosing. Only one patient completed the planned 50
days on study at 60 pgkg- .
Differential leucocyte counts during treatment with GM-
CSF at doses of 10 pgkg- 1 and above revealed that the
white cell increments produced by daily infusions were
caused by increased numbers of neutrophil and eosinophil
polymorphs. The percentage of neutrophils fell at each dose
level (from a mean of 76% of the total count before GM-
CSF to a mean of 64% after 10 days of infusions) whereas
the percentage of eosinophils rose (to comprise a mean of
18% of the total leucocyte count after 10 days of GM-CSF).
There was no significant rise in any other haematological
parameter (including platelets and reticulocytes).
Toxicity
There was no significant alteration of any of the parameters
of renal or hepatic function and no neutralising antibodies to
GM-CSF were detected throughout the study at any dose
level. At doses above 1 pgkg-I, all patients experienced
pyrexias (> 37.5°C), after the first two infusions of GM-
CSF. These were clinically insignificant and resolved within
1-2 hours. Bone pain (occurring predominantly in the
lumbar vertebrae) was experienced by nine patients (one at
lpgkg- 1, one at 3pgkg-1, one at l0pgkg- 1, two at
30 pgkg - 1 and four at 60 pgkg -1). The pain usually
occurred within 5-10 minutes of commencing the infusion
and varied in severity from aching discomfort (three
patients) to very severe pain which required sedation and
opiate analgesia (three patients). This symptom did not
occur until the fourth or fifth infusion but often increased in
severity with subsequent exposure to GM-CSF. The pain
resolved with completion of the infusion.
Two patients (at 3 pgkg-1) experienced generalised
pruritus which began after the third day of treatment with
GM-CSF. The symptom was not relieved with anti-
histamines but resolved within 4 days of discontinuing
GM-CSF.
The most serious toxicity occurred at a dose level of
60 pgkg-1. One patient was admitted on day 7 of the study
with a 4-hour history of left-sided chest pain and dyspnoea.
He was in atrial fibrillation and had a mild pyrexia. Serial
ECGs and cardiac enzymes revealed no evidence of a
myocardial infarction; he returned to sinus rhythm within 12
hours of admission. No further GM-CSF was given and the
patient was asymptomatic by the day after admission. Four
days later, while preparing to return home, he suddenly
collapsed and could not be resuscitated. At post mortem he
was found to have a large fresh left-sided pulmonary
embolus. The primary tumour had been in the pancreas and
it was felt that the embolism was more likely to have arisen
as a complication of the neoplasm than to have been due to
the administration of GM-CSF.
Two other patients developed an acute onset of left-sided
chest pain (one at day 7 and one at day 8 of GM-CSF)
which was typical of pericarditis in its description. Both had
sinus tachycardias, mild pyrexias and audible pericardial
friction rubs. Small pericardial effusions were noted on
cardiac ultrasonography. GM-CSF was discontinued and the
symptoms resolved with non-steroidal anti-inflammatory
agents.
One patient with pulmonary metastases from an osteo-
sarcoma became acutely dyspnoeic 10 hours after each
infusion of GM-CSF. He required oxygen during these
episodes, which each lasted 4-5 hours. GM-CSF was
discontinued after two infusions in the second phase of daily
treatments.
Tumour responses
All patients eligible for this study had documented
progressive metastatic disease before entry. Regular
monitoring of evaluable sites of tumour revealed stabilisation
of disease in seven patients throughout the duration of the
study (and for a minimum of 20 days thereafter) and one
patient with heavily pretreated liposarcoma involving the
chest wall and axilla experienced a significant (> 50%)
reduction in tumour volume after the fifth infusion of GM-
CSF. The response continues 6 months after completing the
study.
Discussion
This study has demonstrated that rhGM-CSF administered
by short daily intravenous infusions, at doses of 10pgkg-'
and above, results in up to a four-fold increase of the
peripheral leucocyte count over 10 days. There was a
significant increment of both neutrophils and eosinophils but
no other haematological parameters were affected by GM-
CSF. There was a transient neutropaenia immediately
following the commencement of each infusion and this may
be due to increased uptake of leucocytes by the lungs
(Devereux et al., 1987).
The triphasic rise of leucocytes seen during the 10-day
administration of GM-CSF in this study was not observed in
primates (Donahue et al., 1986) or humans with AIDS
(Groopman et al., 1987) or myelodysplasia (Vadhan-Raj et
al., 1987) who received prolonged administration of GM-
CSF. The pattern of response is quite different from that
seen with G-CSF (the other myeloid colony-stimulating
factor undergoing clinical trials), which produces an
immediate and sustained rise of the white cell count,
presumably relating to its putative effect on later stages of
commitment of granulocyte precursors (Bronchud et al.,
1987). It is probable that the increase seen over the first 3
days of GM-CSF administration is due to demargination of
mature bone marrow leucocytes and the second phase of
leucocyte increase results from cells which are produced de
novo as a result of the action of GM-CSF on bone marrow
precursor cells. These data suggest that GM-CSF could be
expected to reduce the degree of myelosuppression associated
with chemotherapy, as neutropaenia usually occurs 10-15
days after administration of cytotoxic agents - at least 48
hours after the maximal leucocytosis which would be
induced by GM-CSF. A preliminary report using GM-CSF
after combination chemotherapy for patients with sarcomas
suggests a significantly higher median nadir white cell count
and shortened period of neutropaenia as a result of
administration of GM-CSF (Antman et al., 1988).
The neutrophil counts induced by GM-CSF at doses above
10pgkg-1 were significantly higher but, unfortun-
ately, these greater doses were associated with increased
toxicity. The toxicity determined the maximum tolerated
dosage at 60 ,gkg-1. Only one patient was able to completeGM-CSF INFUSIONS 145
the planned 50 days on study at this dosage but three others
experienced chest pain. A diagnosis of pericarditis was made
in two of these and in both instances the symptoms resolved
rapidly after discontinuing GM-CSF. Pericarditis was seen in
transgenic mice that had continual high serum levels of
endogenously produced GM-CSF and was ascribed to the
production of platelet-derived growth factor (PDGF), fibro-
blast growth factor (FGF) and other biologically active
molecules by activated macrophages (Lang et al., 1987). The
third patient who experienced chest pain died 4 days after
cessation of administration of GM-CSF and was found to
have had a pulmonary embolus as the terminal event. His
extensive pancreatic neoplasm rather than the administration
of GM-CSF was felt to be the more likely cause of his
embolism. A fourth patient with metastatic osteosarcoma
developed severe transient dyspnoea after each infusion of
GM-CSF and a similar syndrome ascribed to capillary leak
with pulmonary oedema has been described in two patients
receiving doses of 32 jugkg-1 following high dose chemo-
therapy and autologous bone marrow rescue (Brandt et al.,
1988).
The observation of a significant regression of lymph node
metastases in a patient with previously treated soft tissue
sarcoma (and possible arrest of growth of metastatic disease
in seven other patients) was particularly interesting.
Macrophages activated by GM-CSF in vitro have been
shown to have antitumour activity (Grabstein et al., 1986)
and this study suggests that the same effect may also occur
in vivo. Such an effect would be particularly important if
GM-CSF is used as an adjunct to chemotherapy. As far as
we are aware, this is the first observation of a tumour
response occurring after the administration of a myeloid
colony-stimulating factor.
The half life of all haemopoietic colony stimulating factors
is short in vivo and previous work has shown that a
continuous exposure to these factors is necessary for
maximum proliferative effect on bone marrow precursor cells
(Metcalf, 1985). This study has shown that even half-hour
infusions of GM-CSF produce significant increments of
leucocyte counts but that at doses above 30 pgkg-1 there is
no clear dose-response relationship but increased toxicity.
Further studies aimed at optimising the route of
administration of GM-CSF to provide a more continuous
blood level throughout the 24 hours, either by subcutaneous
injections or by continuous infusion, are underway so that
the same biological effect can be seen at a lower dose to
obviate the toxicity of this highly promising new agent.
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